Ribo Expands Beyond Liver with Ex-Hepatic Delivery Data at RNA Leaders Europe
Event summary
- Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference on March 19, 2026.
- RiboPepSTAR™ platform demonstrates successful kidney delivery in preclinical studies.
- Seven liver-targeting programs in clinical trials and $6B+ in global licensing deals for RiboGalSTAR™.
- Preclinical development underway for cardiac, adipose, muscle, and CNS disorders.
The big picture
Ribo's shift from liver-focused RiboGalSTAR™ to ex-hepatic applications with RiboPepSTAR™ reflects the broader industry trend toward expanding siRNA therapeutic reach. With $6B+ in licensing deals backing its liver programs, Ribo is positioning itself as a key player in next-generation RNA delivery technologies. Success in kidney and other critical organs could significantly broaden its market potential.
What we're watching
- Technology Validation
- How RiboPepSTAR™'s performance in kidney delivery translates to other ex-hepatic targets.
- Market Expansion
- Whether Ribo can sustain momentum beyond liver-targeting therapies.
- Competitive Positioning
- The pace at which competitors develop similar ex-hepatic delivery platforms.
Related topics